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| INTRODUCTION
Patients undergoing dialysis are at increased risk for developing atrial fibrillation or venous thromboembolism (VTE) compared with patients with normal renal function. [1] [2] [3] [4] [5] [6] These medical indications pose the need for oral anticoagulation in this population, and for many years warfarin has been the only oral anticoagulation option for end stage renal disease (ESRD) patients.
Warfarin has been shown to have a narrow therapeutic window in the ESRD population. 7 The described bleeding rates for warfarin use in hemodialysis patients range from 0.10 to 0.54 events/personyear. 8 In a recent meta-analysis assessing warfarin use in patients with atrial fibrillation and chronic kidney disease (CKD), warfarin increased the risk of major bleeding in patients with ESRD on renal replacement therapy without decreasing risk of stroke or mortality. 9 Available retrospective cohort data using warfarin for atrial fibrillation in patients with ESRD on hemodialysis suggests controversy in whether clinical benefits outweigh the bleeding risk. [4] [5] [6] [10] [11] [12] [13] [14] Warfarin is also associated with increased vascular calcification in ESRD patients on dialysis leading to increased cardiovascular events, strokes, and mortality. [15] [16] [17] A number of additional factors may complicate anticoagulant use in those with ESRD on hemodialysis. In addition to their known uremic platelet dysfunction, many patients have cardiovascular risk factors or indications for antiplatelet medications, both of which may increase their risk for bleeding with anticoagulation therapy. 18, 19 International Normalized Ratio (INR) results may be fluctuant and unpredictable in ESRD on hemodialysis and time in therapeutic range is poor. 20, 21 The aforementioned dilemmas underscore a need for additional anticoagulation options in ESRD patients on hemodialysis.
Apixaban is an oral direct factor Xa inhibitor approved in the United States for use in patients with non-valvular atrial fibrillation (NVAF), VTE treatment or secondary/extended prophylaxis, or deep vein thrombosis (DVT) prophylaxis post total hip/total knee arthroplasty. 22 While prospective studies demonstrated favorable safety and efficacy with apixaban compared with warfarin, they excluded dialysis patients. [23] [24] [25] [26] Apixaban has a 27% renal excretion of the parent compound. 22 Wang et al. administered a single dose of apixaban 5 mg to healthy patients and two doses of apixaban 5 mg to hemodialysis patients. Relative to non-ESRD subjects, the authors found that ESRD patients experienced a 36% increase in apixaban area under the curve (AUC), no increase in maximum concentration levels and a negligible decrease in apixaban removal after a 4-hour hemodialysis session. 27 Based off of these results in ESRD, the FDA recommended dose adjustment for patients with atrial fibrillation with age >80 years or weight <60 kg as previously described in apixaban trials. 22 Recent pharmacokinetic and retrospective study data describe further experience with apixaban use in ESRD patients on dialysis. A pharmacokinetic steady state dosing study demonstrated that apixaban 2.5 mg twice daily dosing in hemodialysis patients resulted in drug exposure comparable to apixaban 5 mg twice daily dosing in patients with preserved renal function; in contrast, apixaban 5 mg twice daily dosing in hemodialysis patients led to supra-therapeutic drug exposure and trough levels. 28 In a retrospective, matchedcohort study in patients with severe renal disease, Stanton et al.
found no statistically significant difference in the major or overall bleeding event rate of patients taking apixaban vs warfarin, including the subgroup of patients on dialysis. 29 In addition, continuation of apixaban after inpatient admission, the daily dose of apixaban, and the number of hemodialysis sessions have been associated with an increased risk of bleeding. 30 The University of Virginia Medical Center's Hematology Consult service has recommended apixaban use in some of its dialysis patients. The purpose of this study was to compare bleeding events between maintenance dialysis patients at our institution on apixaban vs warfarin.
| ME THODS
We performed a retrospective single institution review of clinical outcomes with the use of apixaban compared with warfarin in ESRD patients maintained on dialysis at a large academic hospi- Further exclusions included lack of follow-up documentation and switching anticoagulation during analysis period. Figure 1 shows further exclusion criteria and a schematic for analysis. Follow-up time was 10 months for both groups. The primary outcome was overall bleeding event rate, which we defined as experiencing at least one bleeding event after at least two doses of starting apixaban and at least one bleeding event after 5 days of starting warfarin. We based censoring time off of the known pharmacokinetics of warfarin and apixaban. Secondary outcomes were major bleeding events, clinically relevant non-major bleeding events, minor bleeding, recurrent VTE in patients treated for DVT or pulmonary embolism, and ischemic stroke in patients with NVAF.
Major bleeding was defined using International Society of In addition, we calculated HAS-BLED scores for patients who were on warfarin or apixaban for NVAF to describe the risk of bleeding demonstrated in previous studies. 
| Statistical analysis
We made unadjusted comparisons of apixaban and warfarin patients using student's t, chi-square and Fisher's exact tests. We made adjusted comparisons of the likelihood of experiencing a bleeding event using a multivariable logistic model that included the following patient risk factors: anticoagulant, sex, race, age at start of anticoagulation, weight at start of anticoagulation, indication, type of concurrent anti-platelet, and a history of alcohol use, cardiovascular disease, bleeding or stroke. We performed all analyses using SAS version 9.4 (SAS Institute Inc., Cary, NC).
| RE SULTS
A total of 375 patients met the inclusion criteria for this review. Of the 153 patients in the apixaban group, 74 were ultimately included;
of the 222 warfarin patients, 50 were ultimately included ( Figure 1 ).
Demographic and clinical baseline characteristics were similar between the groups ( Table 1 ).
The sample patients experienced a total of 35 bleeding events during the analysis time period. Of these, 15 events were classified as major. During the analysis period, there were also eight recurrent VTE events ( Table 2 ).
The warfarin group experienced more bleeding events than the apixaban group (42% and 18.9%, respectively; P = .01), with a lower prevalence of major bleeding in the apixaban group (5.4% vs 22% in the warfarin group; P = .01). The overall bleeding event rate in the apixaban and warfarin groups was 0.31 and 0.47 events per person year, respectively, with a lower rate of major bleeding events per person-year in the apixaban group (0.07 vs 0.24). We also conducted adjusted analyses looking at the likelihood of experiencing a bleeding event. Using multivariable logistic regression adjusting for several demographic and clinical factors, we found that apixaban patients were significantly less likely to experience a bleeding event in the study period than were warfarin patients (OR = 0.15; 95% CI = 0.05-0.46; P = .001). Results are shown in Table 3 . As expected, patients who reported experiencing a bleed prior to the study were significantly more likely to experience a bleed during the study (OR = 4.78; 95% CI = 1.50-15.21; P = .01). However, we were surprised to find that African-American patients were less likely than their white counterparts to have a bleeding event (OR = 0.31; 95% CI = 0.1-0.9; P = .03). No other factors were found to be significant predictors of a bleeding event.
| Apixaban group
In the apixaban group, most patients (46%; n = 34) required anticoagulation for the treatment of VTE, whereas 39.2% (n = 29) and 14.9% (n = 11) of patients required anticoagulation for NVAF and prophylaxis of VTE, respectively. Most patients were on therapeutic dosing of apixaban 5 mg every 12 hours (79.7%; n = 59).
The remaining patients were on 2.5 mg twice daily (20.3%; n = 15) and met the criteria for either dose reduction (n = 4) or lifelong prophylactic anticoagulation dosing (n = 11). For patients receiving acute treatment of DVT, only three patients received the apixaban loading dose of 10 mg twice daily for 7 days prior to the maintenance dose, 5 mg every 12 hours. The average time patients were on anticoagulation in the study period was 7.9 months.
There were 25 patients (33.8%) on concurrent antiplatelet medications, including 21 patients on aspirin and four patients on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin.
Most of the patients had been on warfarin prior to initiation of apixaban (n = 40; 54%), and one patient was on rivaroxaban prior to diagnosis of ESRD.
There were 14 bleeding events recorded in patients anticoagulated with apixaban (Table 4) , with four being major, seven being clinically relevant non-major and three events classified as minor.
The average HAS-BLED score was 3.2. The average time to bleed in the patients who were on apixaban was 5.98 months. One patient had two major upper gastrointestinal (GI) bleeds, with each event occurring approximately 3 days after being initiated on apixaban after two separate occasions. The two other major bleeds were both secondary to a GI origin. None of the major bleeding events directly resulted in a patient death; however, after each case of major bleeding, the patients were discontinued from apixaban therapy. Other bleeding events are shown in Table 4 . Interestingly, only three of these bleeding events occurred with patients taking 2.5 mg dose of apixaban and were all clinically relevant non-major bleeding events. In all minor bleeding events, patients were continued on apixaban.
| Warfarin group
The indication for anticoagulation for the patients in the warfarin group comprised NVAF (58%; n = 29), treatment of VTE (36%; n = 18) and prophylaxis of VTE (6%; n = 3). The average amount of time TA B L E 1 Baseline demographic and clinical characteristics of the study patients patients were on warfarin during the study period was 10.8 months.
Only one patient was on peritoneal dialysis. Most patients (52%; n = 26) were on concurrent antiplatelet medications, with 18 patients on aspirin and 8 patients on DAPT with clopidogrel and aspirin.
There were 21 patients who had a bleeding event while on warfarin. The average time to bleed in patients on warfarin was 7.2 months.
Of those events, 11 patients (22%) had major bleeds, nine patients (18%) had clinically relevant non-major bleeds and one patient (2%) had a minor bleed. Major bleeds included GI origin, hemopericardium, hemothorax, retroperitoneal bleeds, and a subarachnoid hemorrhage. Other types of bleeding events in the patients taking warfarin described in 
| Recurrent VTE/stroke
Given that maintenance dialysis patients are at increased risk for recurrent vascular complications, we also analyzed the rate of recurrent VTE in each group. Patients taking apixaban had a lower VTE recurrence than warfarin patients (4.4% vs 28.6%, respectively). No patients in either the apixaban group or the warfarin group suffered from an ischemic stroke. One patient in the warfarin group had a suspected transient ischemic attack (TIA); however, the patient did not demonstrate any evidence of stroke on imaging.
| D ISCUSS I ON
While there is no current consensus on the safety for apixaban use in ESRD patients, our study suggests that in maintenance dialysis patients, apixaban may be associated with a lower bleeding rate than warfarin. Given the high prevalence of atrial fibrillation and VTE in the ESRD population, it is important to find anticoagulation options that have a low risk of bleeding with favorable efficacy. To the authors' knowledge, our study is the first retrospective cohort study to find a statistically significant lower bleeding event rate in patients with ESRD on apixaban vs warfarin.
The primary outcome of overall bleeding rate was significantly less frequent in patients on apixaban compared with patients on warfarin. The warfarin bleeding event rate of 0.47 events per person-year was within the range published in a systematic review of warfarin anticoagulation in hemodialysis patients. 8 The apix- Numbers displayed are odds ratios with their corresponding 95% confidence intervals. These values are from a logistic model predicting the probability of a patient experiencing a bleeding event. VTE, venous thromboembolism; PPX, prophylaxis; DAPT, Dual antiplatelet therapy. Bold rows signify characteristics that were found to be statistically significant.
those who did not. Interestingly, of the patients who had a bleeding event, 11 and five were on warfarin or apixaban, respectively, with concurrent antiplatelet use.
We found no different levels of risk of recurrent stroke between the apixaban and warfarin groups. The mean CHA 2 DS 2 -VASc was 4.1 and 4.0 for apixaban and warfarin, respectively. There was one TIA event in the warfarin group; however, no evidence of stroke was seen on imaging at the time of presentation. Also, we observed a lower risk of recurrent episodes of VTE while on anticoagulation with apixaban compared with warfarin. This is consistent with evidence from the AMPLIFY and AMPLIFY-EXT trials. 23, 24 Our study provides a depiction of safe use of apixaban treatment in a cohort of ESRD patients on maintenance dialysis, which we hope will expand the anticoagulation armamentarium for a population of patients in whom the safety of warfarin is in question. Available retrospective data using warfarin for atrial fibrillation in ESRD on hemodialysis patients evoke debate over whether clinical benefits outweigh the bleeding risk. [4] [5] [6] [7] 11, 13, 33 Assessment is difficult due to heterogeneity in these trials, which differ in design, definitions of endpoints, and measurements of clinical efficacy or laboratory monitoring. Published trials question the benefit of warfarin use as there is disparity in the results characterizing stroke risk; some studies find no difference in stroke risk when warfarin is used, 5, 6, [10] [11] [12] whereas others associate warfarin with increased stroke risk 13, 14 and two studies found that warfarin use decreased stroke risk. 33, 34 Our findings are similar to those reported by Stanton et al. in regard to decreased bleeding events in patients on apixaban with severe renal impairment; however, they analyzed patients with acute kidney injury (AKI), CKD and ESRD, while our study analyzed only patients with ESRD on dialysis. 29 Most patients in their trial were on the reduced dose of apixaban at 2. 
TA B L E 4 Bleeding events on anticoagulation
In conclusion, our study suggests apixaban may be a safe and effective anticoagulation option in patients with ESRD on dialysis.
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